Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Beam Therapeutics Inc.

BEAM · Nasdaq · CIK 0001745999 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

19 Form 4 transaction lines observed in the same window
11 sales · 8 option, withholding, award, gift or other lines

Last qualifying purchaseNo qualifying purchase is present in the local Form 4 history.

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Evans John M.CEO
○▼○▼○▼○▼
Ciaramella GiuseppePresident
○○
FMR LLCTenPercentOwner,Other
▼▼
Simon AmyChief Medical Officer
▼▼
Cavanagh Bethany JSVP, Finance and Treasurer
▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot.—

Recent Form 4 activity

0Purchases
30Sales
13Other Form 4 lines
23SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING11 sale line(s) · context only
OTHER8 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-4.9%
3M
-10.9%
6M
-25.2%
12M
-13.7%

Volatility & liquidity

Volatility
74.2%
Beta
—
Avg daily value
USD 42.7M

Valuation

Market cap
USD 2.4B
P/E
—

Fundamentals

Profit margin
-57.2%
ROE
-6.5%
Industry
Biotechnology

Market data

Price data up to: 2026-10-16 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-07-28 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
27,548,815
Previous report
25,884,796
Avg daily volume
1,800,518
Days to cover
15.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

No qualifying code P equity purchase is present in the local Form 4 history.

Form 4 evidence

43 transaction lines in the latest 365-day window; 432 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-16Evans John M.Sale (S)Common Stock25,000USD 23.98USD 599,595SEC filing ↗
2026-10-16Evans John M.Option exercise / conversion (M)Common Stock25,000USD 1.03USD 25,750SEC filing ↗
2026-10-15Evans John M.Sale (S)Common Stock25,000USD 23.57USD 589,150SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-16Evans John M.Sale (S)Common Stock25,000USD 23.98USD 599,595SEC filing ↗
2026-10-16Evans John M.Option exercise / conversion (M)Common Stock25,000USD 1.03USD 25,750SEC filing ↗
2026-10-15Evans John M.Sale (S)Common Stock25,000USD 23.57USD 589,150SEC filing ↗
2026-10-15Evans John M.Option exercise / conversion (M)Common Stock25,000USD 1.03USD 25,750SEC filing ↗
2026-10-01Cavanagh Bethany JSale (S)Common Stock187USD 24.41USD 4,565SEC filing ↗
2026-09-24Ciaramella GiuseppeGift (G)Common Stock123,407USD 0.00USD 0SEC filing ↗
2026-07-27Simon AmySale (S)Common Stock16,667USD 25.74USD 429,009SEC filing ↗
2026-06-30Simon AmySale (S)Common Stock373USD 34.73USD 12,954SEC filing ↗
2026-06-30Evans John M.Sale (S)Common Stock25,000USD 34.30USD 857,602SEC filing ↗
2026-06-30Evans John M.Option exercise / conversion (M)Common Stock25,000USD 1.03USD 25,750SEC filing ↗
2026-06-29Evans John M.Sale (S)Common Stock25,000USD 35.49USD 887,282SEC filing ↗
2026-06-29Evans John M.Option exercise / conversion (M)Common Stock25,000USD 0.76USD 19,031SEC filing ↗
2026-06-26FMR LLCSale (S)Common Stock251,488USD 35.26USD 8,867,467SEC filing ↗
2026-06-25FMR LLCSale (S)Common Stock33,372USD 35.12USD 1,172,025SEC filing ↗
2026-06-17Ciaramella GiuseppeOption exercise / conversion (M)Common Stock35,505USD 0.96USD 34,228SEC filing ↗
2026-04-01Simon AmySale (S)Common Stock6,700USD 24.58USD 164,686SEC filing ↗
2026-04-01Evans John M.Sale (S)Common Stock30,078USD 24.58USD 739,317SEC filing ↗
2026-04-01Ciaramella GiuseppeSale (S)Common Stock11,810USD 24.58USD 290,290SEC filing ↗
2026-04-01Cavanagh Bethany JSale (S)Common Stock3,242USD 24.58USD 79,688SEC filing ↗
2026-04-01Bellon ChristineSale (S)Common Stock5,956USD 24.58USD 146,398SEC filing ↗
2026-02-24Ciaramella GiuseppeSale (S)Common Stock35,000USD 32.00USD 1,120,000SEC filing ↗
2026-02-24Ciaramella GiuseppeOption exercise / conversion (M)Common Stock35,000USD 17.00USD 595,000SEC filing ↗
2026-01-30Evans John M.Sale (S)Common Stock25,000USD 28.35USD 708,871SEC filing ↗
2026-01-30Evans John M.Option exercise / conversion (M)Common Stock25,000USD 0.67USD 16,750SEC filing ↗
2026-01-29Evans John M.Sale (S)Common Stock25,000USD 29.38USD 734,517SEC filing ↗
2026-01-29Evans John M.Option exercise / conversion (M)Common Stock25,000USD 0.67USD 16,750SEC filing ↗
2026-01-22Cavanagh Bethany JSale (S)Common Stock6,198USD 35.00USD 216,930SEC filing ↗
2026-01-22Bellon ChristineSale (S)Common Stock1,371USD 34.00USD 46,614SEC filing ↗
2026-01-20Cavanagh Bethany JSale (S)Common Stock3,034USD 30.12USD 91,384SEC filing ↗
2026-01-15Bellon ChristineSale (S)Common Stock18,629USD 34.62USD 644,857SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerBEAM
CIK0001745999
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history432 transaction lines from 2020-02-10 to 2026-10-16
0 P purchase lines · 247 S sale lines · 185 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.